NCT05384769 Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
| NCT ID | NCT05384769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Lung Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2022-07-29 |
| Primary Completion | 2029-01-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2022-07-29 with a primary completion date of 2029-01-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer. Currently, a low dose computed tomography (CT) scan is used to screen for lung cancer, however, due to various factors, few high-risk patients are screened. Liquid biopsy utilizes technology that can detect small amounts of DNA shed by cancer cells and may be able to spot lung cancer at an earlier stage. If a positive result comes back from the liquid biopsy, a patient may be more willing to get a low dose CT (LDCT) scan, possibly confirming the biopsy's findings and thus leading to more early lung cancer detection.
Eligibility Criteria
Inclusion Criteria: * Documented written informed consent of the participant. * Age 50-80 years. * Smoking history of \>= 20 pack-years and if quit, quit within 15 years. * Received referral for counseling for lung cancer screening and would qualify for LDCT. * Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center). * Willingness to provide blood sample. * English speaking. * Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT. Exclusion Criteria: * Symptoms of lung cancer. * Chest CT scan or chest positron emission tomography (PET)/CT within 12 months. * Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer. * Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.
Contact & Investigator
Dan Raz, MD
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT05384769 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05384769 currently recruiting?
Yes, NCT05384769 is actively recruiting participants. Contact the research team at draz@coh.org for enrollment information.
Where is the NCT05384769 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT05384769 clinical trial?
NCT05384769 is sponsored by City of Hope Medical Center. The principal investigator is Dan Raz, MD at City of Hope Medical Center. The trial plans to enroll 108 participants.